Supplier

BAXTER CZECH spol. s r.o.

Value won

CZK 32.9m

Across 3 contracts won

A Czech Republic supplier, with 3 awarded contracts, most recently 1 years ago.

Czech Republic(inferred)

Track BAXTER CZECH spol. s r.o.

We'll email you when they win a contract · Free · No card

Value won

CZK 32.9m

Across 3 contracts won

Contract history

3 entries

Most recent
21 May 2025
1 years ago
Biggest
CZK 21.8m
Supply of Trace Elements for Parent…
Average size
CZK 11m
Across 3 priced
Last 12 months
0
entries

Won · 3

Supply of Trace Elements for Parenteral UseCZK 21,770,000 · 21 May 2025 Sevoflurane Supply and Equipment InstallationCZK 8,970,000 · 19 May 2025 Supply of Propofol for Medical UseCZK 2,130,000 · 6 May 2025

Mar 25Apr 25May 25Jun 25Jun 25

Opportunities

Showing awarded · 3

AwardedHealthcare & MedicalCzech Republic

Supply of Trace Elements for Parenteral Use

This public procurement contract involves the supply of medicinal products for parenteral administration containing trace elements (ATC groups B05XA31, B05XA20). These products are intended for the treatment of patients with approved indications according to the Summary of Product Characteristics (S

CZK 21,770,000INSTITUTE OF CLINICAL AND EXPERIMENTAL MEDICINE

Published 21 May 2025

AwardedHealthcare & MedicalCzech Republic

Sevoflurane Supply and Equipment Installation

This public procurement contract involves the ongoing supply of medicinal products classified under ATC group N01AB08, specifically the active ingredient Sevoflurane. Additionally, it includes the delivery and installation of fully functional vaporizers that are free from defects and compatible with

CZK 8,970,000PARDUBICE REGION HOSPITALS INC

Published 19 May 2025

AwardedHealthcare & MedicalCzech Republic

Supply of Propofol for Medical Use

This public procurement contract involves the supply of medicinal products for parenteral administration containing the active ingredient propofol at a concentration of 2% (ATC group N01AX10). These products are intended for the treatment of patients in approved indications according to the Summary

CZK 2,130,000INSTITUTE OF CLINICAL AND EXPERIMENTAL MEDICINE

Published 6 May 2025